Frequently Asked Questions
What are the purine levels in Restaurant Chinese Sweet And Sour Chicken?
While exact purine measurements for Restaurant Chinese Sweet And Sour Chicken are limited, it is classified as None for gout. This rating draws on established scientific consensus and typical values for its food group. Consult our full review for dietary recommendations.
Is Restaurant Chinese Sweet And Sour Chicken high in fructose?
Restaurant Chinese Sweet And Sour Chicken contains about 3.0g of fructose per 100g, which is a moderate amount. In the liver, fructose speeds up purine breakdown, which can nudge uric acid upward. It is not extremely high, but total fructose consumption is still worth watching for gout.
Can I eat Restaurant Chinese Sweet And Sour Chicken with gout?
Restaurant Chinese Sweet And Sour Chicken is classified as MODERATE risk for gout. may contain moderate purines. Occasional small servings may be workable, though it is best skipped during an active flare. Track how your body reacts and check with your healthcare provider for advice tailored to you.
What food category does Restaurant Chinese Sweet And Sour Chicken belong to?
Restaurant Chinese Sweet And Sour Chicken is classified under Meat in our gout food database. Knowing its food group helps you weigh it appropriately within your broader gout diet plan. Browse other meat items to compare purine and fructose levels across similar foods.
What are gout-friendly alternatives to Restaurant Chinese Sweet And Sour Chicken?
Instead of Restaurant Chinese Sweet And Sour Chicken, consider choosing meat options rated SAFE in our gout database — these have low purine (under 50 mg/100g) and low fructose (under 2g/100g). Browse our meat category page to find the best substitutes for your gout diet plan.
Data Quality
This entry uses T2-level data:
At least one dimension is directly measured; the other is based on scientific consensus.
Sources include USDA FoodData Central (public domain, CC0 1.0), the USDA+ODS-NIH Database for the Purine Content of Foods Release 2.0 (2025), Kaneko et al. Biol Pharm Bull 2014, and ACR/EULAR clinical guidelines.